

[Navigation überspringen](#)

[Plenary Session, June 17 THE RATHL STUDY CRUK/07/033: ADDITION OF THIOTEPA & RITUXIMAB TO ANTIMETABOLITES IMPROVES OUTCOME IN PRIMARY CNS LYMPHOMA: 1st RANDOMIZATION OF THE JELSG32 TRIAL; NIVOLUMAB IN R/R LYMPHOID MALIGNANCIES & CLASSICAL HODGKIN LYMPHOMA \(CA209-039\).](#)

[Mundipharma Satellite Symposium at 13-ICML CLL and follicular NHL: Critical review of the current guidelines and future perspectives - Chairs: Prof. John Gribben, London \(UK\) & Prof. Michele Ghilmini, Bellinzona \(Switzerland\)](#)

[Press Conference with Franco Cavalli, Riccardo Dalla-Favera & Jonathan W. Friedberg](#)

-